The ADRB3 gene encodes the beta-3 adrenergic receptor (β3-AR), a member of the adrenergic receptor family and a G-protein coupled receptor (GPCR) that plays a central role in regulating lipolysis, thermogenesis, and energy expenditure. While classically studied in the context of metabolic disorders and obesity, emerging research over the past decade has revealed significant connections between β3-AR signaling and neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD)[@arch2011].
The β3-AR is uniquely expressed across multiple tissue types, including adipose tissue, skeletal muscle, cardiac tissue, and select brain regions. Its expression in the central nervous system, particularly in the hypothalamus and brainstem, positions it as a key modulator of metabolic homeostasis, stress responses, and potentially neuroprotective pathways. The receptor signals primarily through Gs proteins, leading to activation of adenylate cyclase and increased intracellular cAMP levels, though it can also engage β-arrestin-mediated signaling pathways that activate MAPK cascades[@park2020].
Given the strong epidemiological link between metabolic dysfunction and neurodegenerative diseases, β3-AR has emerged as a potential therapeutic target. The FDA-approved β3-AR agonist mirabegron (used for overactive bladder) has shown promise in preclinical studies for neuroprotection, though its limited central nervous system penetration remains a challenge for treating CNS disorders. Ongoing research aims to develop brain-penetrant β3-AR agonists with enhanced therapeutic potential for neurodegenerative conditions[@yang2021].
| Beta-3 Adrenergic Receptor | |
|---|---|
| Gene Symbol | ADRB3 |
| Full Name | Adrenoceptor Beta 3 |
| Chromosome | 8p11.23 |
| NCBI Gene ID | [629](https://www.ncbi.nlm.nih.gov/gene/629) |
| OMIM | 109760 |
| Ensembl ID | ENSG00000125378 |
| UniProt ID | [P13945](https://www.uniprot.org/uniprot/P13945) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Metabolic Syndrome |
The ADRB3 gene is located on chromosome 8p11.23 and spans approximately 2.5 kilobases of genomic DNA. The gene consists of two exons, with the coding sequence contained entirely within the second exon. This relatively simple genomic structure is characteristic of adrenergic receptor genes, which have evolved through gene duplication events from a common ancestor[@arch2011].
The β3-AR protein consists of 402 amino acids and possesses the characteristic seven-transmembrane domain structure common to all GPCRs. The protein includes:
The ligand-binding pocket is formed within the transmembrane domains, with the characteristic binding site for catecholamines (epinephrine, norepinephrine) involving conserved residues in helices III, V, VI, and VII. The β3-AR has lower affinity for classical catecholamines compared to β1 and β2 adrenergic receptors, which contributes to its distinct pharmacological profile.
Upon ligand binding, β3-AR primarily couples to Gs proteins, leading to activation of adenylate cyclase and increased intracellular cAMP levels. This triggers downstream signaling cascades:
Beyond classical Gs signaling, β3-AR can also signal through β-arrestin-dependent pathways:
This biased signaling capability provides opportunities for developing biased agonists that selectively activate desired pathways while minimizing side effects[@jiang2014].
β3-AR exhibits distinct expression patterns across tissues:
| Tissue | Expression Level | Primary Function |
|---|---|---|
| White Adipose Tissue | High | Lipolysis, thermogenesis |
| Brown Adipose Tissue | Very High | Non-shivering thermogenesis |
| Skeletal Muscle | Moderate | Metabolic regulation |
| Heart | Low-Moderate | Cardiomyocyte function |
| Gastrointestinal Tract | Moderate | Gut motility |
| Hypothalamus | Low | Metabolic homeostasis |
| Brainstem | Low | Autonomic regulation |
The relatively low expression in the brain compared to peripheral tissues has historically limited interest in CNS effects, but emerging research demonstrates important central nervous system functions[@arch2011].
β3-AR plays a central role in energy homeostasis:
These metabolic effects are particularly relevant to neurodegenerative diseases, given the strong link between metabolic dysfunction and AD/PD risk[@jiang2014].
Multiple neuroprotective mechanisms have been attributed to β3-AR signaling:
β3-AR signaling affects several processes relevant to AD pathogenesis[@park2020]:
AD brains exhibit profound glucose hypometabolism, particularly in the hippocampus and cerebral cortex. β3-AR plays important roles in:
Epidemiological studies have shown that individuals with metabolic syndrome have a significantly increased risk of developing AD, establishing β3-AR as a potential therapeutic target for addressing metabolic contributors to neurodegeneration.
Chronic neuroinflammation is a hallmark of AD pathogenesis. β3-AR signaling modulates microglial activation:
Studies in mouse models demonstrate that chronic β3-AR agonist treatment reduces microglial activation markers and improves cognitive function[@choi2016].
The relationship between β3-AR and amyloid processing is complex:
Recent studies using APP/PS1 transgenic mice demonstrate that chronic mirabegron treatment reduces amyloid plaque burden and improves spatial memory performance[@zhao2024].
Emerging evidence suggests β3-AR may modulate tau pathology:
Research demonstrates that β3-AR activation reduces tau phosphorylation through modulation of GSK-3β activity[@park2023].
In PD, β3-adrenergic receptors may play several important roles[@chen2021]:
β3-AR agonists have shown protective effects in multiple PD models:
The neuroprotective effects appear mediated through activation of the cAMP/PKA pathway and downstream antioxidant responses.
Some evidence links β3-AR to modulation of dopaminergic neuron function:
Clinical observations suggest ADRB3 polymorphisms may affect response to dopaminergic therapies:
Given the strong link between metabolic syndrome and neurodegeneration:
ADRB3 variants associated with visceral obesity increase AD risk:
β3-AR signaling significantly affects insulin sensitivity:
Type 2 diabetes is a well-established risk factor for AD, and β3-AR modulators may address this comorbidity.
β3-AR affects blood pressure and vascular function:
Vascular contributions to dementia make β3-AR an attractive target for addressing cerebrovascular aspects of neurodegeneration[@tang2024].
β3-adrenergic receptor agonists approved for clinical use include:
| Drug | Indication | CNS Penetration |
|---|---|---|
| Mirabegron | Overactive bladder | Limited |
| Vibegron | Overactive bladder | Limited |
| Solabegron | IBS, OAB | Limited |
While approved for peripheral indications, the limited CNS penetration has prompted research into brain-penetrant analogs.
New β3-AR agonists in development include:
Preclinical and clinical studies are evaluating these next-generation compounds for neurodegenerative disease indications[@xie2024].
Potential therapeutic applications include:
ADRB3 polymorphisms affect drug response:
Studies demonstrate that the rs4994 polymorphism modulates AD progression and treatment response, highlighting the importance of personalized medicine approaches[@huang2024].
Cell culture models used to study β3-AR include:
Animal models for β3-AR research include:
Human research approaches include:
Development of biomarkers for β3-AR-related therapies includes:
Novel approaches to enhance CNS delivery include:
β3-AR modulators may combine with: